PureTech Health FY2024 EPS Decreased by Leerink Partnrs

PureTech Health plc (NASDAQ:PRTCFree Report) – Analysts at Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for PureTech Health in a research note issued on Tuesday, November 19th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings of ($4.31) per share for the year, down from their prior forecast of ($4.27). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for PureTech Health’s current full-year earnings is ($4.32) per share.

Separately, Leerink Partners initiated coverage on PureTech Health in a research note on Monday, September 9th. They set an “outperform” rating and a $45.00 price objective for the company.

Get Our Latest Report on PureTech Health

PureTech Health Stock Up 0.4 %

Shares of PureTech Health stock opened at $21.78 on Thursday. PureTech Health has a 12 month low of $17.08 and a 12 month high of $34.00. The business has a fifty day simple moving average of $20.53 and a 200 day simple moving average of $23.36.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PureTech Health stock. Birch Hill Investment Advisors LLC bought a new stake in PureTech Health plc (NASDAQ:PRTCFree Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 302,000 shares of the company’s stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned 1.26% of PureTech Health at the end of the most recent quarter. 0.04% of the stock is owned by institutional investors.

PureTech Health Company Profile

(Get Free Report)

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.

See Also

Earnings History and Estimates for PureTech Health (NASDAQ:PRTC)

Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.